Clinical observation of metformin in the treatment of diabetes mellitus type 2 complicated with sarcopenia in elderly patients

ZHONG Xuemei; CHEN Min; LING Yayun; ZHANG Bingqian

doi:10.6039/j.issn.1001-0408.2025.06.16

您当前的位置：

首页 >

文章列表页 >

Clinical observation of metformin in the treatment of diabetes mellitus type 2 complicated with sarcopenia in elderly patients

更新时间：2025-09-25

- Clinical observation of metformin in the treatment of diabetes mellitus type 2 complicated with sarcopenia in elderly patients
- ZHONGGUO YAOFANG Vol. 36, Issue 6, Pages: 732-736(2025)
- 作者机构：
  
  1.重庆医药高等专科学校临床医学院呼吸内分泌教研室，重庆　401331
  2.重庆医药高等专科学校附属第一医院内分泌科，重庆　400060
  3.川北医学院附属医院内分泌科，四川南充　637000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.06.16
  CLC： R969.4
- Received：17 October 2024，
  
  Revised：2025-02-17，
  
  Accepted：26 February 2025，
  
  Published：30 March 2025
- 稿件说明：
移动端阅览
钟雪梅,陈敏,凌雅韵,等.二甲双胍治疗老年2型糖尿病合并肌少症的临床观察[J].中国药房,2025,36(06):732-736.

ZHONG Xuemei,CHEN Min,LING Yayun,et al.Clinical observation of metformin in the treatment of diabetes mellitus type 2 complicated with sarcopenia in elderly patients[J].ZHONGGUO YAOFANG,2025,36(06):732-736.
钟雪梅,陈敏,凌雅韵,等.二甲双胍治疗老年2型糖尿病合并肌少症的临床观察[J].中国药房,2025,36(06):732-736. DOI： 10.6039/j.issn.1001-0408.2025.06.16.

ZHONG Xuemei,CHEN Min,LING Yayun,et al.Clinical observation of metformin in the treatment of diabetes mellitus type 2 complicated with sarcopenia in elderly patients[J].ZHONGGUO YAOFANG,2025,36(06):732-736. DOI： 10.6039/j.issn.1001-0408.2025.06.16.

摘要

目的

探讨二甲双胍治疗老年2型糖尿病（T2DM）合并肌少症患者的疗效及安全性。

方法

选择2022年1月至2024年1月于重庆医药高等专科学校附属第一医院治疗的老年T2DM合并肌少症患者，按随机数字表法分为对照组（70例）和观察组（70例）。在常规干预的基础上，对照组患者于睡前皮下注射甘精胰岛素注射液+每日早、中、晚餐前30 min皮下注射人胰岛素注射液；观察组患者在对照组的基础上口服盐酸二甲双胍缓释片0.5 g，每日1次。两组患者均连续治疗24周。比较两组患者糖代谢指标[空腹血糖（FBG）、餐后2 h血糖（2 hBG）、糖化血红蛋白（HbA1c）]、胰岛素抵抗指数（HOMA-IR）、四肢骨骼肌指数（ASMI）、握力、步行速度、脂代谢指标[血清总甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）]、血清学标志物[超敏C反应蛋白（hs-CRP）、白细胞介素6（IL-6）、铁蛋白水平]及生活质量，并记录不良反应发生情况。

结果

对照组和观察组分别有65、63例患者完成本研究。治疗后，两组患者FBG、2 hBG、HbA1c、HOMA-IR、TG、TC及观察组患者的hs-CRP、IL-6、铁蛋白水平均较治疗前显著降低（

＜0.05），且观察组患者的HOMA-IR显著低于对照组（

＜0.05）；观察组患者的握力、步行速度、活动能力和日常生活情况指数均较治疗前及对照组显著增加（

＜0.05）。两组患者的不良反应发生率均为2.86%。

结论

二甲双胍可降低老年T2DM合并肌少症患者的炎症因子及血清铁蛋白水平，促进肌肉质量和力量的恢复，改善胰岛素抵抗，提高患者生活质量，且未增加不良反应的发生。

Abstract

OBJECTIVE

To investigate the efficacy and safety of metformin in the treatment of diabetes mellitus type 2 （T2DM） complicated with sarcopenia in elderly patients.

METHODS

From January 2022 to January 2024， clinical data from eligible patients with T2DM complicated with sarcopenia treated at the First Affiliated Hospital of Chongqing Medical and Pharmaceutical College were collected. Patients were randomly assigned into control group （70 cases） and observation group （70 cases） using a random number table. Both groups received routine interventions； control group additionally received subcutaneous injections of Insulin glargine injection before bedtime and Human insulin injection 30 minutes before breakfast， lunch and dinner every day. In addition to the same treatments as the control group， the observation group was administered 0.5 g of Metformin hydrochloride sustained-release tablets orally once daily. Both groups were treated continuously for 24 weeks. Comparisons were made between the two groups in terms of glucose metabolism indexes [fasting blood glucose （FBG）， 2 h postprandial blood glucose （2 hBG）， and glycosylated hemoglobin （HbA1c）]， homeostasis model assessment of insulin resistance （HOMA-IR）， appendicular skeletal mass muscle index （ASMI）， grip strength， walking speed， lipid metabolism indexes [serum total triglyceride （TG）， total cholesterol （TC）， low-density lipoprotein cholesterol （LDL-C）， and high-density lipoprotein cholesterol （HDL-C）]， serological markers [high-sensitivity C reactive protein （hs-CRP）， interleukin-6 （IL-6）， and ferritin levels] and quality of life. The occurrence of ADR was recorded in both groups.

RESULTS

65 patients in the control group and 63 patients in the observation group completed this study， respectively. After treatment， the levels of FBG， 2 hBG， HbA1c， HOMA-IR， TG and TC in both groups， and the levels of hs-CRP， IL-6 and ferritin in observation group were all significantly reduced compared to those before treatment （

＜0.05）， and the HOMA-IR in observation group was significantly lower than control group （

＜0.05）； additionally， the grip strength， walking speed， and scores for daily living and activity abilities of observation group were increased than those before treatment and the control group （

＜0.05）. The incidence of adverse drug reactions in both groups was 2.86%.

CONCLUSIONS

Metformin can reduce inflammatory factors and ferritin levels， promote the recovery of muscle mass and strength， improve insulin resistance， and quality of life in elderly patients with T2DM complicated with sarcopenia， and does not increase the occurrence of adverse drug reactions.

关键词

Keywords

references

CHO M R ， LEE S ， SONG S K . A review of sarcopenia pathophysiology，diagnosis，treatment and future direction [J ] . J Korean Med Sci ， 2022 ， 37 （ 18 ）： e146 .

XIE W Q ， HE M ， YU D J ， et al . Mouse models of sarco-penia：classification and evaluation [J ] . J Cachexia Sarcopenia Muscle ， 2021 ， 12 （ 3 ）： 538 - 554 .

崔华，王朝晖，吴剑卿，等 . 老年人肌少症防控干预中国专家共识：2023 [J ] . 中华老年医学杂志， 2023 ， 42 （ 2 ）： 144 - 153 .

CUI H ， WANG C H ， WU J Q ， et al . Chinese expert consensus on prevention and intervention for elderly with sarcopenia：2023 [J ] . Chin J Geriatr ， 2023 ， 42 （ 2 ）： 144 - 153 .

钟文，谢春光，高泓，等 . 糖尿病与肌少症关系研究新进展 [J ] . 中国糖尿病杂志， 2017 ， 25 （ 7 ）： 662 - 665 .

ZHONG W ， XIE C G ， GAO H ， et al . Recent progress of relationship between diabetes and sarcopenia [J ] . Chin J Diabetes ， 2017 ， 25 （ 7 ）： 662 - 665 .

赵予，孟德泉，徐茜，等 . 基于CT诊断肌少症与老年2型糖尿病伴骨质疏松的相关性 [J ] . 中国老年学杂志， 2023 ， 43 （ 5 ）： 1046 - 1050 .

ZHAO Y ， MENG D Q ， XU Q ， et al . Correlation between sarcopenia and senile type 2 diabetes mellitus with osteoporosis based on CT [J ] . Chin J Gerontol ， 2023 ， 43 （ 5 ）： 1046 - 1050 .

QAISAR R ， KARIM A ， MUHAMMAD T ， et al . Metformin improves sarcopenia-related quality of life in geriatric adults：a randomized controlled trial [J ] . Arch Med Res ， 2024 ， 55 （ 4 ）： 102998 .

TEZZE C ， AMENDOLAGINE F I ， NOGARA L ， et al . A combination of metformin and galantamine exhibits synergistic benefits in the treatment of sarcopenia [J ] . JCI Insight ， 2023 ， 8 （ 15 ）： e168787 .

中华医学会糖尿病学分会 . 中国2型糖尿病防治指南：2020年版 [J ] . 中华糖尿病杂志， 2021 ， 13 （ 4 ）： 315 - 409 .

Chinese Diabetes Society of the Chinese Medical Association . Reaction to guideline for the prevention and treatment of type 2 diabetes mellitus in China：2020 edition [J ] . Chin J Diabetes Mellit ， 2021 ， 13 （ 4 ）： 315 - 409 .

CHEN L K ， LIU L K ， WOO J ， et al . Sarcopenia in Asia：consensus report of the Asian working group for sarco-penia [J ] . J Am Med Dir Assoc ， 2014 ， 15 （ 2 ）： 95 - 101 .

LIM T O ， MORAD Z . Reliability，validity and discriminatory ability of Spitzer’s QL-index in dialysis patients [J ] . Med J Malaysia ， 1998 ， 53 （ 4 ）： 392 - 400 .

肖建中 . 二甲双胍的作用机制新进展 [J ] . 中华糖尿病杂志， 2024 ， 16 （ 7 ）： 735 - 739 .

XIAO J Z . New progress in the mechanism of metformin [J ] . Chin J Diabetes Mellit ， 2024 ， 16 （ 7 ）： 735 - 739 .

《二甲双胍临床应用专家共识》更新专家组 . 二甲双胍临床应用专家共识：2023年版 [J ] . 中华内科杂志， 2023 ， 62 （ 6 ）： 619 - 630 .

Expert Group for Updating Chinese Expert Consensus on Metformin in Clinical Practice . Chinese expert consensus on metformin in clinical practice：2023 update [J ] . Chin J Intern Med ， 2023 ， 62 （ 6 ）： 619 - 630 .

杨俊朋，王丹钰，韦伟，等 . 老年2型糖尿病患者血糖目标范围内时间与肌少症的相关性研究 [J ] . 中华内分泌代谢杂志， 2022 ， 38 （ 3 ）： 179 - 185 .

YANG J P ， WANG D Y ， WEI W ， et al . Time in range of glucose and sarcopenia in elderly patients with type 2 diabetes [J ] . Chin J Endocrinol Metab ， 2022 ， 38 （ 3 ）： 179 - 185 .

SALOM VENDRELL C ， GARCÍA TERCERO E ， MORO HERNÁNDEZ J B ， et al . Sarcopenia as a little-recognized comorbidity of type Ⅱ diabetes mellitus：a review of the diagnosis and treatment [J ] . Nutrients ， 2023 ， 15 （ 19 ）： 4149 .

MESINOVIC J ， FYFE J J ， TALEVSKI J ， et al . Type 2 diabetes mellitus and sarcopenia as comorbid chronic disea-ses in older adults：established and emerging treatments and therapies [J ] . Diabetes Metab J ， 2023 ， 47 （ 6 ）： 719 - 742 .

黄安乐，卜子涵，薛梦婷，等 . 肌少症患者外周血炎性因子的Meta分析 [J ] . 中国骨质疏松杂志， 2021 ， 27 （ 7 ）： 969 - 975 .

HUANG A L ， BU Z H ， XUE M T ， et al . Peripheral inflammatory markers in the patients with sarcopenia：a meta-analysis [J ] . Chin J Osteoporos ， 2021 ， 27 （ 7 ）： 969 - 975 .

GELLHAUS B ， BÖKER K O ， SCHILLING A F ， et al . Therapeutic consequences of targeting the IGF-1/PI3K/Akt/FOXO3 axis in sarcopenia：a narrative review [J ] . Cells ， 2023 ， 12 （ 24 ）： 2787 .

吴梦娇，陈超，施毕旻 . 血清铁蛋白在绝经后女性2型糖尿病并发肌少症患者的变化 [J ] . 中华骨质疏松和骨矿盐疾病杂志， 2020 ， 13 （ 3 ）： 222 - 228 .

WU M J ， CHEN C ， SHI B M . Change of serum ferritin in postmenopausal women with type 2 diabetes and sarcopenia [J ] . Chin J Osteoporos Bone Miner Res ， 2020 ， 13 （ 3 ）： 222 - 228 .

PYRGIOTI E E ， KARAKOUSIS N D ， GEORGAKOPOULOS P N ， et al . Metformin in type 2 diabetes：evidence for its beneficial effects on frailty and sarcopenia [J ] . Curr Diabetes Rev ， 2024 ， 20 （ 3 ）： e270723219177 .

Views

191

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Network meta-analysis of first-line treatment of metastatic colorectal cancer with different chemotherapy combination regimens

Efficacy and safety of ruxolitinib in the treatment of myelofibrosis

Efficacy and safety of luspatercept in the treatment of myelodysplastic syndrome anemia：a single-group rate meta-analysis

Improve effects of aromatase inhibitors on the height of children with short stature

Clinical observation of doxycycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children under 8 years of age

Related Author

ZHANG Xiaoqing

LIU Shuai

ZHANG Kai

JI Beibei

LUAN Wei

WANG Wanwan

YE Jun

CHENG Hai

Related Institution

Inner Mongolia Clinical Medical College， Inner Mongolia Medical University

Day-care Unit， Inner Mongolia Armed Police Hospital

Dept. of Medical Oncology， Inner Mongolia People’s Hospital

Dept. of Hematology， the Third People’s Hospital of Bengbu

Dept. of Hematology， the Affiliated Hospital of Xuzhou Medical University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰